Trilogy Capital Inc. purchased a new position in Amgen, Inc. (NASDAQ:AMGN) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,146 shares of the medical research company’s stock, valued at approximately $195,000.
A number of other hedge funds have also bought and sold shares of AMGN. Pzena Investment Management LLC boosted its stake in Amgen by 79,361.6% in the 1st quarter. Pzena Investment Management LLC now owns 1,341,311 shares of the medical research company’s stock worth $228,667,000 after purchasing an additional 1,339,623 shares during the period. Amundi Pioneer Asset Management Inc. boosted its stake in Amgen by 382.3% in the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 1,389,775 shares of the medical research company’s stock worth $241,682,000 after purchasing an additional 1,101,649 shares during the period. Aristotle Capital Management LLC raised its holdings in shares of Amgen by 44.7% during the 4th quarter. Aristotle Capital Management LLC now owns 2,193,090 shares of the medical research company’s stock worth $381,378,000 after acquiring an additional 677,373 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of Amgen by 16.9% during the 4th quarter. Renaissance Technologies LLC now owns 4,579,445 shares of the medical research company’s stock worth $796,365,000 after acquiring an additional 661,745 shares in the last quarter. Finally, Millennium Management LLC raised its holdings in shares of Amgen by 1,245.3% during the 4th quarter. Millennium Management LLC now owns 519,141 shares of the medical research company’s stock worth $90,279,000 after acquiring an additional 480,551 shares in the last quarter. Institutional investors and hedge funds own 78.27% of the company’s stock.
Several analysts have recently issued reports on the company. TheStreet raised Amgen from a “c+” rating to a “b-” rating in a report on Friday, May 25th. BidaskClub raised Amgen from a “hold” rating to a “buy” rating in a report on Monday, June 18th. ValuEngine cut Amgen from a “buy” rating to a “hold” rating in a report on Monday, April 2nd. Cann reaffirmed a “buy” rating on shares of Amgen in a report on Friday, June 8th. Finally, Mizuho reaffirmed a “buy” rating and set a $200.00 price objective on shares of Amgen in a report on Friday. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $194.77.
Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, April 24th. The medical research company reported $3.47 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.24 by $0.23. Amgen had a return on equity of 35.80% and a net margin of 9.67%. The company had revenue of $5.55 billion for the quarter, compared to analyst estimates of $5.44 billion. During the same quarter in the prior year, the firm posted $3.15 EPS. Amgen’s quarterly revenue was up 1.6% compared to the same quarter last year. sell-side analysts forecast that Amgen, Inc. will post 13.67 EPS for the current year.
In related news, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction on Monday, May 14th. The stock was sold at an average price of $174.10, for a total transaction of $265,502.50. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold a total of 4,575 shares of company stock worth $809,851 in the last 90 days. 0.19% of the stock is currently owned by insiders.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.